NCT02845804

Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis

Harmonizing Optimal Strategy for Treatment of Coronary Atherosclerotic Lesions- Registry-based Study on the Effect and Safety of Xience Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerotic Lesions: HOST-Alpine Registry

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 1,533 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The objectives of this study are 1. To establish a prospective registry of the whole patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™ stent 2. To evaulate the long-term efficacy and safety of coronary stenting with the Xience Xpedition™/Alpine™ stent 3. To compare the long-term efficacy and safety of coronary stenting between the Xience Xpedition™/Alpine ™ stent and other contemporary drug-eluting stents which had established their own registry

Detailed description

Secondary endpoints of this study are Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI Target vessl failure Composite rate of cardiac death and any MI, 3 years Composite rate of all death and any MI Composite rate of all death, any MI, and any repeat revascularization Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy

Conditions

• Coronary Artery Disease
• Percutaneous Coronary Intervention
• Acute Coronary Syndrome
• Angina Pectoris

Interventions

Type	Name	Description
DEVICE	Alpine

Timeline

• Start date: 2015-07-01
• Primary completion: 2018-07-01
• Completion: 2021-07-01
• First posted: 2016-07-27
• Last updated: 2016-07-27

Locations

20 sites across 1 country: South Korea